LT3229843T - Farmacinė kompozicija, jos paruošimo būdas ir naudojimas - Google Patents

Farmacinė kompozicija, jos paruošimo būdas ir naudojimas

Info

Publication number
LT3229843T
LT3229843T LTEP15801384.7T LT15801384T LT3229843T LT 3229843 T LT3229843 T LT 3229843T LT 15801384 T LT15801384 T LT 15801384T LT 3229843 T LT3229843 T LT 3229843T
Authority
LT
Lithuania
Prior art keywords
preparation
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
LTEP15801384.7T
Other languages
English (en)
Inventor
Marie-Edith MEYRE
Agnes Pottier
Matthieu Germain
Céline BERJAUD
Audrey DARMON
Original Assignee
Curadigm Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curadigm Sas filed Critical Curadigm Sas
Publication of LT3229843T publication Critical patent/LT3229843T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP15801384.7T 2014-11-25 2015-11-24 Farmacinė kompozicija, jos paruošimo būdas ir naudojimas LT3229843T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306871 2014-11-25
PCT/EP2015/077423 WO2016083331A1 (en) 2014-11-25 2015-11-24 Pharmaceutical composition, preparation and uses thereof

Publications (1)

Publication Number Publication Date
LT3229843T true LT3229843T (lt) 2020-05-25

Family

ID=52013979

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15801384.7T LT3229843T (lt) 2014-11-25 2015-11-24 Farmacinė kompozicija, jos paruošimo būdas ir naudojimas

Country Status (11)

Country Link
US (2) US20170258937A1 (lt)
EP (1) EP3229843B1 (lt)
JP (1) JP6722688B2 (lt)
AR (1) AR102778A1 (lt)
DK (1) DK3229843T3 (lt)
ES (1) ES2774365T3 (lt)
LT (1) LT3229843T (lt)
PL (1) PL3229843T3 (lt)
PT (1) PT3229843T (lt)
TW (1) TW201628644A (lt)
WO (1) WO2016083331A1 (lt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116380C2 (uk) 2013-05-30 2018-03-12 Нанобіотікс Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки
FI3229776T3 (fi) 2014-11-25 2023-08-15 Curadigm Sas Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt
DK3236934T3 (da) 2014-11-25 2024-08-19 Curadigm Sas Farmaceutisk sammensætning, fremstilling og anvendelser deraf
ES2890662T3 (es) 2014-11-25 2022-01-21 Curadigm Sas Composiciones farmacéuticas, preparación y usos de las mismas
HK1246160A1 (zh) 2015-05-28 2018-09-07 Nanobiotix 用作治疗性疫苗的纳米粒子
AU2021389027A1 (en) * 2020-11-30 2023-06-29 Anbition S.R.L. Multi-specific human albumin nanoparticles decorated with antibody fragments and loaded with cytotoxics

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69529054T2 (de) 1994-02-28 2003-08-21 Nanopharm Ag System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
CN100509847C (zh) * 2003-08-01 2009-07-08 安美基公司 结晶肿瘤坏死因子受体2多肽
WO2005063305A1 (en) 2003-12-22 2005-07-14 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
WO2007122956A1 (ja) 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
US20090181076A1 (en) 2006-05-04 2009-07-16 University Of South Australia Drug Release From Nanoparticle-Coated Capsules
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
US9403789B2 (en) 2008-02-21 2016-08-02 Sequoia Pharmaceuticals, Inc. Benzofuran-containing amino acid inhibitors of cytochrome P450
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
WO2010048623A2 (en) * 2008-10-26 2010-04-29 Board Of Regents, The University Of Texas Systems Medical and imaging nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
JP5649137B2 (ja) 2010-02-17 2015-01-07 国立大学法人神戸大学 放射線治療剤
PL2552438T3 (pl) * 2010-03-26 2016-12-30 Sposoby leczenia raka wątrobowokomórkowego
WO2012051220A1 (en) * 2010-10-11 2012-04-19 Wichita State University Composite magnetic nanoparticle drug delivery system
US20140227343A1 (en) 2011-01-31 2014-08-14 Centre National De La Recherche Scientifique Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles
PL2670394T3 (pl) 2011-01-31 2019-03-29 Nanobiotix Układy do dostarczania nanocząstek, ich otrzymywanie i zastosowania
BR112014023200A2 (pt) * 2012-03-20 2018-09-18 Albert Einstein College Of Medicine Of Yeshiva University uso de uma composição
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) * 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US20140213765A1 (en) 2013-01-25 2014-07-31 I-Liang Lee Albumin tissue scaffold
UA116380C2 (uk) 2013-05-30 2018-03-12 Нанобіотікс Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
DK3236934T3 (da) 2014-11-25 2024-08-19 Curadigm Sas Farmaceutisk sammensætning, fremstilling og anvendelser deraf
ES2890662T3 (es) 2014-11-25 2022-01-21 Curadigm Sas Composiciones farmacéuticas, preparación y usos de las mismas
WO2016083336A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
FI3229776T3 (fi) 2014-11-25 2023-08-15 Curadigm Sas Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt

Also Published As

Publication number Publication date
JP6722688B2 (ja) 2020-07-15
EP3229843B1 (en) 2020-01-01
DK3229843T3 (da) 2020-03-09
EP3229843A1 (en) 2017-10-18
US11191846B2 (en) 2021-12-07
US20180339062A1 (en) 2018-11-29
PT3229843T (pt) 2020-03-06
PL3229843T3 (pl) 2020-06-29
US20170258937A1 (en) 2017-09-14
TW201628644A (zh) 2016-08-16
JP2017538782A (ja) 2017-12-28
ES2774365T3 (es) 2020-07-20
WO2016083331A1 (en) 2016-06-02
AR102778A1 (es) 2017-03-22

Similar Documents

Publication Publication Date Title
IL276695B (en) Antibodies, pharmaceutical preparations and their uses
IL290114A (en) Pharmaceutical preparations, their preparation and uses
GB201409471D0 (en) Pharmaceutical composition
ZA201509307B (en) Pharmaceutical composition, preparation and uses thereof
GB201409488D0 (en) Pharmaceutical composition
PL3223796T3 (pl) Kompozycje farmaceutyczne, ich wytwarzanie i zastosowania
IL252397A0 (en) Pharmaceutical preparations, their preparation and uses
GB201409485D0 (en) Pharmaceutical composition
ZA201703398B (en) Pharmaceutical composition and methods
PT3229843T (pt) Composição farmacêutica, a sua preparação e as suas utilizações
IL262929A (en) Preparations for treatment, methods for their preparation and their uses
ZA201508726B (en) Pharmaceutical composition
ZA201502073B (en) Pharmaceutical composition
PL3089740T3 (pl) Kompozycja farmaceutyczna
IL249073A0 (en) Cytin-glucan complex, its preparation and uses
SG10201504332VA (en) Pharmaceutical Composition
GB2509426B (en) Clomazone composition, its preparation and use thereof
IL284405A (en) Pharmaceutical composition, preparation and uses thereof
TH1501007100A (th) องค์ประกอบทางเภสัชกรรม, การเตรียม และการใช้ของมัน